Figure 3.
Kaplan-Meier time-to-first event curves for death and MACE. Patients in the DNMT3A/TET2 VAF≥2% group (n = 60) had higher incidence of death (a) and MACE (b) compared to the no-DNMT3A/TET2 VAF≥2% group (n = 425). Further, we divided our cohort into subjects without a VAF≥1% (n = 374); with a VAF of 1, 2% (n = 51); a VAF of 2–10% (n = 46); and a VAF≥10% (n = 14), and found that the higher VAF was associated with poorer outcome (c,d). P-values are for log-rank tests.